Cholinergic synapses are ubiquitous in the human central nervous system. Their high
density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic …

Although Alzheimer's disease (AD) is the world's leading cause of dementia and the
population of patients with AD continues to grow, no new therapies have been approved in …

Alzheimer's disease (AD) is the most common cause for dementia worldwide. Until recently,
all approved treatments for AD were symptomatic and not disease modifying. On 7 June …

Currently there are 850,000 people with Alzheimer's disease in the UK, with an estimated
rise to 1.1 million by 2025. Alzheimer's disease is characterised by the accumulation of …

Despite the significant public health issue that it poses, only five medical treatments have
been approved for Alzheimer's disease (AD) and these act to control symptoms rather than …

Alzheimer's disease (AD) is the foremost type of dementia that afflicts considerable morbidity
and mortality in aged population. Several transcription molecules, pathways, and molecular …

Alzheimer's disease, a major and increasing global health challenge, is an irreversible,
progressive form of dementia, associated with an ongoing decline of brain functioning. The …

Scientific evidence collected over the past 4 decades suggests that a loss of cholinergic
innervation in the cerebral cortex of patients with Alzheimer's disease is an early pathogenic …

The neurotransmitter acetylcholine (ACh) can regulate neuronal excitability by acting on the
cys-loop cation-conducting ligand-gated nicotinic ACh receptor (nAChR) channels. These …

Arsenic toxicity is a worldwide health concern as several millions of people are exposed to
this toxicant via drinking water, and exposure affects almost every organ system in the body …